Giving Economic Added Value to Research


Genoma España (Foundation for Development and Research in Genomics and Proteomics) is a public foundation with links to the state, but with a strong vocation for business, with the objective to promote research in genomics and to develop biotechnology in Spain.
Thus, the creation of Genoma España promotes active participation in the second phase or the genome era, which will bring notable advances and applications in the fields of health, food science and the environment.
Genoma España was founded with the mission of becoming the engine and link between agents in the Spanish biotechnology sector (researchers, the business community, institutions and investors) with a clear projection toward society. In addition to promoting and co-ordinating research conducted in Spain in genomics and proteomics, another objective of Genoma España is to make better use of the results of research, giving it market value and guiding it towards the development of the biotechnology business sector. Genoma España likewise acts as an observatory of the research being conducted and carries out prospective tasks. Its other objectives include promoting the participation of civil society and mobilizing private resources toward Spanish universities and public research institutes.
In the framework of fulfilling these objectives, the activities of Genoma España are focused principally on providing direct support for research in genomics and proteomics and creating bioenterprises, supporting different research groups, centers and networks in this field, promoting technology transfer, conducting awareness campaigns and developing relations with national and international institutions and entities.
An Open Platform
To implement these objectives and projects, Genoma España's organization is structured around a Board of Directors with administrative, management and representative functions, which is fully open to incorporating both businesses and private institutions.
Genoma España also has two advisory boards, a Business Council in charge of all matters relating to biotechnology enterprises, especially those involved with genomics and proteomics, and a Scientific Advisory Committee for scientific matters.
The Business Council is composed of representatives of companies in the sector or in related fields. And the Scientific Advisory Committee includes prestigious scientists in the sector and representatives of Spanish or foreign institutions who can provide valuable input.
The structure of Genoma España likewise includes three executive bodies (an Executive Committee, General Directorate and Management Department) and three operative units (the Strategic Studies Unit, Sales and Training Unit, and Coordination and Special Actions Unit), in addition to its Economic Control Unit.
During 2003 three international projects in genomics and proteomics were initiated (in collaboration with Genome Canada) in the fields of human health, plants, and aquiculture, and three technological platforms were set up: the Virtual Bio-informatics Institute, the Spanish DNA Bank and the Spanish Genotyping Center.
These initiatives, and especially the technological platforms, are intended to place the country among the most advanced nations in research and applications derived from genome-related discoveries and to enable it to be present in projects such as the aforementioned Hap-Map/Var-Hap.
At the Service of Society and its Stakeholders
In line with its role of promoting and enhancing the Spanish biotechnology sector, Genoma España has developed a series of products for both researchers and businesses in the sector, potential investors, and governmental agencies. Moreover, this portfolio provides the opportunity to bring together all of these stakeholders.
One of the strong points of the Deal Flow services that Genoma España provides to stakeholders is that these services facilitate the entry of private capital into the sector and minimize investment risks, since Genoma España conducts prescriptive analyses of those projects that have a clear potential for applied research and those products that have commercial interest.
This portfolio of products and services likewise offers benefits to those entities (investors, the business community and institutions) that belong to the Board of Trustees or its Business Council. These benefits include:
- Participation in defining the country's strategies in the area of genomics and in the coordination and follow up after they are put into practice,
- Access to information concerning vigi- lance, prospective and evaluation of technologies, products and knowledge, and
- Evaluation of projects of their interest, contracting those projects with the me- diation of Genoma España, and utiliz- ing their results.
With regard to researchers, Genoma España gives market value to the result of their research and works to support their promotion and mobility with a view to facilitating their participation in major forums and projects. And all of this is in line with its firm intention to strengthen co-operation between the international entities, principally in Europe, which conduct research in their areas of interest.
Knowledge of the map of the human genome also represents new knowledge not included in the teaching curricula of traditional institutions and business schools. Thus, there is a need to design educational programmes to promote the understanding and evaluation of this new economic and scientific environment.
Moreover, Genoma España is concerned with public opinion, since society is the principal beneficiary of the results of the basic and applied research conducted in the area of biotechnology, and specifically in genomics and proteomics. The following applications are clear examples of the potential of these new activities and their impact on society:
- Agriculture and Animal Husbandry
- Nutrition
- Aquaculture and Fisheries
- Animal Health
- Human Health
- Environment
Further information:
Genoma España
Rosario Pino, 14-16, 7°, 28020 Madrid



Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...



Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...



Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...



Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).



Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...



Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...



Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...



Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...



Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%


  • 4SC (D)2.59 EUR-20.31%
  • FORMYCON (D)20.15 EUR-4.37%


  • GALAPAGOS (B)51.86 EUR30.7%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1177.00 DKK22.2%


  • MOBERG PHARMA (S)38.00 SEK-21.8%
  • 4SC (D)2.59 EUR-21.5%
  • FORMYCON (D)20.15 EUR-18.0%


  • KARO BIO (S)30.60 SEK1981.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%


  • BB BIOTECH (D)44.03 EUR-84.5%
  • BIOTEST (D)17.15 EUR-78.1%

No liability assumed, Date: 29.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016